SCHEMBL5207761

SCHEMBL5207761

CCOC(=O)C(C)(Cc1ccc(OCc2ccccc2)cc1)Oc1ccc(C)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 5/20 0.52
PPARG P37231 5/20 0.51
LMNA P02545 2/20 0.50
MAOB P27338 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
PARP10 Q53GL7 1/20 0.49
ALDH1A1 P00352 2/20 0.48
OPRK1 P41145 1/20 0.48
NR1H4 Q96RI1 1/20 0.48
PPARD Q03181 1/20 0.47
ALOX5 P09917 1/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47
NR4A1 P22736 1/20 0.47
NR4A2 P43354 1/20 0.47
NR4A3 Q92570 1/20 0.47
FFAR1 O14842 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2807182 0.95 PPARG (0.55) PPARAPPARGLMNAMAOBL3MBTL1
SCHEMBL14176244 0.95 LMNA (0.54) PPARAPPARGLMNAMAOBL3MBTL1
SCHEMBL5113057 0.92 RAB9A (0.52) PPARAPPARGLMNAMAOBL3MBTL1
SCHEMBL5213397 0.92 PPARG (0.52) PPARAPPARGLMNAMAOBL3MBTL1
SCHEMBL5208740 0.91 PPARA (0.62) PPARAPPARGLMNAMAOBL3MBTL1
SCHEMBL5209756 0.91 MRGPRX4 (0.53) PPARAPPARGLMNAMAOBL3MBTL1
SCHEMBL5205181 0.89 MAOB (0.54) PPARAPPARGLMNAMAOBL3MBTL1
SCHEMBL6713362 0.89 RXRA (0.55) PPARAPPARGLMNAL3MBTL1ALDH1A1
SCHEMBL5992353 0.87 L3MBTL1 (0.53) PPARGLMNAMAOBL3MBTL1PARP10
SCHEMBL5660644 0.87 OPRK1 (0.60) PPARAPPARGLMNAMAOBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1313717-B1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS LILLY CO ELI (US) 2007-10-17 EP disclosed
US-7176224-B2 Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists ELI LILLY AND COMPANY (US) 2007-02-13 US disclosed
US-20040138277-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists ELI LILLY AND COMPANY 2004-07-15 US disclosed
EP-1313717-A1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS ELI LILLY AND COMPANY (US) 2003-05-28 EP disclosed
WO-2002016332-A1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS ELI LILLY AND COMPANY (US) 2002-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138277-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists PPARA, PPARD, PPARG PPARA 1/4885PPARG 3/4885LMNA 3917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.